Home Hero
Home Hero

For your patients’ severe
eosinophilic asthma

Help bring
back balance

By preventing exacerbations
& by reducing daily OCS dose

NUCALA is indicated for the add-on maintenance treatment of patients 6 years and older with severe asthma with an eosinophilic phenotype. NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus.


Hospital icon

Exacerbation reduction

Trial 2 53% reduction in exacerbations vs placebo1*
61% reduction in exacerbations requiring hospitalization/ED visit vs placebo*

Real-world study: Interim analysis at 12 months2
Associated with

Reduction image

Secondary objective. Results are descriptive.

See study limitations

Pill icon

OCS reduction

Trial 3: Greater percent reduction in daily OCS dose (Weeks 20-24) while maintaining asthma control vs placebo (P=0.008; Primary Endpoint.)3

Reduction in daily OCS dose3

OCS reduction image

Results are descriptive.
Sensitivity analysis to the primary endpoint.

Lung icon

Long-term data

4.5-year open-label study:
Exacerbation rate 0.68/year (Secondary Endpoint)4§

Associated with

Long-term exacerbation reduction image

Results are descriptive. Median duration 3.8 years.

Real-world study: Prespecified interim analysis of a 2-year prospective, observational cohort study (N=368). Secondary objective (shown above): Post-exposure NUCALA 0.27/year vs baseline 1.14/year; rate ratio 0.23 (95% CI: 0.18, 0.30). Primary objective (Exacerbations/year): Post-exposure NUCALA 1.43 vs baseline 4.63 (69% reduction; rate ratio 0.31; 95% CI: 0.27, 0.35). Results are descriptive. Study limitations: May not reflect final results. Real-world studies are designed to evaluate associations among variables and not to definitively establish causality. Limitations important when interpreting results: no comparator arm; differences in patient populations and data collection vs randomized controlled trials.2

§4.5-year open-label study: Assessed safety, immunogenicity, and efficacy of NUCALA (N=347). Secondary endpoint: Mean exacerbations/year: 0.68 (95% CI: 0.60, 0.78) with NUCALA + asthma controller in all patients; based on exacerbations reported from the time a patient enrolled until study withdrawal (median duration 3.8 years). Rate prior to study start was 1.74.4 Results are descriptive.

*Trial 2: 32-week placebo controlled study (N=576) Primary endpoint: Frequency of exacerbations. NUCALA+SOC 0.83/year, placebo+SOC 1.74/year, P<0.001. Secondary endpoint: Frequency of exacerbations requiring hospitalization and/or ED visit. NUCALA+SOC 0.08/year, placebo+SOC 0.20/year, P=0.02.1

Trial 3: 24-week placebo-controlled study (N=135); Sensitivity analysis to the primary endpoint. NUCALA+SOC 95% CI: 20.0, 75.0; placebo+SOC 95% CI: -20, 33.3.3 Results are descriptive.

NUCALA: Only anti-IL-5 approved for 3 eosinophil-driven diseases

NUCALA is indicated for the:

  • Add-on maintenance treatment of patients 6 years and older with severe eosinophilic asthma (SEA). NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus.
  • Treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).
  • Treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for ≥6 months without an identifiable non-hematologic secondary cause.

See Important Safety Info

Checklist icon

Get your patients started with NUCALA

Steps for accessing NUCALA and other helpful resources for your SEA patients and practice

See patient access & support

NUCALA Autoinjector icon

Administering NUCALA 

NUCALA gives appropriate patients the option to self-administer at home.

See SEA dosing & administration

CI=confidence interval; ED=emergency department; IL=interleukin; MOA=mechanism of action; OCS=oral corticosteroid; SOC=standard of care.